Literature DB >> 21953592

Immune regulation in chronically transfused allo-antibody responder and nonresponder patients with sickle cell disease and β-thalassemia major.

Weili Bao1, Hui Zhong, Xiaojuan Li, Margaret T Lee, Joseph Schwartz, Sujit Sheth, Karina Yazdanbakhsh.   

Abstract

Red blood cell alloimmunization is a major complication of transfusion therapy. Host immune markers that can predict antibody responders remain poorly described. As regulatory T cells (Tregs) play a role in alloimmunization in mouse models, we analyzed the Treg compartment of a cohort of chronically transfused patients with sickle cell disease (SCD, n = 22) and β-thalassemia major (n = 8) with and without alloantibodies. We found reduced Treg activity in alloantibody responders compared with nonresponders as seen in mice. Higher circulating anti-inflammatory IL-10 levels and lower IFN-γ levels were detected in non-alloimmunized SCD patients. Stimulated sorted CD4+ cells from half of the alloimmunized patients had increased frequency of IL-4 expression compared with nonresponders, indicating a skewed T helper (Th) 2 humoral immune response in a subgroup of antibody responders. All patients had increased Th17 responses, suggesting an underlying inflammatory state. Although small, our study indicates an altered immunoregulatory state in alloantibody responders which may help future identification of potential molecular risk factors for alloimmunization.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21953592      PMCID: PMC3618679          DOI: 10.1002/ajh.22167

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  30 in total

1.  Sickle cell anemia as an inflammatory disease.

Authors:  O S Platt
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

Review 2.  Interleukin-10 and the interleukin-10 receptor.

Authors:  K W Moore; R de Waal Malefyt; R L Coffman; A O'Garra
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

3.  Abnormal T-lymphocyte subpopulations associated with transfusion of blood-derived products.

Authors:  C M Kessler; R S Schulof; A L Goldstein; P H Naylor; N L Luban; J F Kelleher; G H Reaman
Journal:  Lancet       Date:  1983-04-30       Impact factor: 79.321

4.  Prospective RBC phenotype matching in a stroke-prevention trial in sickle cell anemia: a multicenter transfusion trial.

Authors:  E P Vichinsky; N L Luban; E Wright; N Olivieri; C Driscoll; C H Pegelow; R J Adams
Journal:  Transfusion       Date:  2001-09       Impact factor: 3.157

5.  Natural killer cell activity and T subpopulations in thalassemia major.

Authors:  A Neri; M Brugiatelli; P Iacopino; V Callea; F Ronco
Journal:  Acta Haematol       Date:  1984       Impact factor: 2.195

6.  Lipid membrane peroxidation in beta-thalassemia major.

Authors:  E A Rachmilewitz; S B Shohet; B H Lubin
Journal:  Blood       Date:  1976-03       Impact factor: 22.113

7.  Current problems and future directions of transfusion-induced alloimmunization: summary of an NHLBI working group.

Authors:  James C Zimring; Lis Welniak; John W Semple; Paul M Ness; Sherrill J Slichter; Steven L Spitalnik
Journal:  Transfusion       Date:  2011-01-20       Impact factor: 3.157

8.  Reduced levels of T-cell subsets CD4+ and CD8+ in homozygous sickle cell anaemia patients with splenic defects.

Authors:  K Gustave Koffi; Duni Sawadogo; Mori Meite; Danho Clotaire Nanho; Estelle S Tanoh; Alain Koffi Attia; Ibrahim Sanogo; Amadou Sangare
Journal:  Hematol J       Date:  2003

9.  Diminished helper/suppressor lymphocyte ratios and natural killer activity in recipients of repeated blood transfusions.

Authors:  J Kaplan; S Sarnaik; J Gitlin; J Lusher
Journal:  Blood       Date:  1984-07       Impact factor: 22.113

10.  Lymphocyte subpopulations in homozygous sickle cell anaemia.

Authors:  M O Adedeji
Journal:  Acta Haematol       Date:  1985       Impact factor: 2.195

View more
  27 in total

1.  Immune Regulation of sickle Cell Alloimmunization.

Authors:  Karina Yazdanbakhsh; Beth H Shaz; Christopher D Hillyer
Journal:  ISBT Sci Ser       Date:  2016-11-15

2.  Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention (CME).

Authors:  Elliott Vichinsky; Lynne Neumayr; Sean Trimble; Patricia J Giardina; Alan R Cohen; Thomas Coates; Jeanne Boudreaux; Ellis J Neufeld; Kristy Kenney; Althea Grant; Alexis A Thompson
Journal:  Transfusion       Date:  2013-07-25       Impact factor: 3.157

3.  The sickle cell mouse lung: proinflammatory and primed for allergic inflammation.

Authors:  Biree Andemariam; Alexander J Adami; Anurag Singh; Jeffrey T McNamara; Eric R Secor; Linda A Guernsey; Roger S Thrall
Journal:  Transl Res       Date:  2015-03-16       Impact factor: 7.012

4.  Protective effect of HLA-DQB1 alleles against alloimmunization in patients with sickle cell disease.

Authors:  Zohreh Tatari-Calderone; Heather Gordish-Dressman; Ross Fasano; Michael Riggs; Catherine Fortier; Andrew D Campbell; Dominique Charron; Victor R Gordeuk; Naomi L C Luban; Stanislav Vukmanovic; Ryad Tamouza
Journal:  Hum Immunol       Date:  2015-10-22       Impact factor: 2.850

5.  Immunologic characterization suggests reduced alloimmunization in a murine model of thalassemia intermedia.

Authors:  Weili Bao; Hui Zhong; Karina Yazdanbakhsh
Journal:  Transfusion       Date:  2014-05-05       Impact factor: 3.157

6.  Combination peptide immunotherapy suppresses antibody and helper T-cell responses to the RhD protein in HLA-transgenic mice.

Authors:  Lindsay S Hall; Andrew M Hall; Wendy Pickford; Mark A Vickers; Stanislaw J Urbaniak; Robert N Barker
Journal:  Haematologica       Date:  2014-01-17       Impact factor: 9.941

7.  Red blood cell alloimmunization is influenced by the delay between Toll-like receptor agonist injection and transfusion.

Authors:  Rahma Elayeb; Marie Tamagne; Philippe Bierling; France Noizat-Pirenne; Benoît Vingert
Journal:  Haematologica       Date:  2015-10-01       Impact factor: 9.941

Review 8.  How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions.

Authors:  France Pirenne; Karina Yazdanbakhsh
Journal:  Blood       Date:  2018-05-03       Impact factor: 22.113

9.  The Lombardy Rare Donor Programme.

Authors:  Nicoletta Revelli; Maria Antonietta Villa; Cinzia Paccapelo; Maria Cristina Manera; Paolo Rebulla; Anna Rita Migliaccio; Maurizio Marconi
Journal:  Blood Transfus       Date:  2013-02-21       Impact factor: 3.443

10.  Molecular matching for Rh and K reduces red blood cell alloimmunisation in patients with myelodysplastic syndrome.

Authors:  Gláucia A S Guelsin; Camila Rodrigues; Jeane E L Visentainer; Paula De Melo Campos; Fabíola Traina; Simone C O Gilli; Sara T O Saad; Lilian Castilho
Journal:  Blood Transfus       Date:  2014-06-12       Impact factor: 3.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.